肾切除与消融治疗后复发性肾细胞癌:影像学视角
本文为综述,讨论肾细胞癌经肾切除或影像引导消融(射频、冷冻、微波)治疗后的随访影像方案、不同治疗方式后的复发模式、影像表现及常见与少见转移部位;指出不同机构指南在随访频率、检查方式和持续时间上存在差异。
要点
- 不同机构指南对肾细胞癌治疗后随访影像的频率、检查方式和持续时间存在差异。
- 影像引导消融(射频、冷冻、微波)近十年在小肿瘤治疗中日益普及。
- 综述涵盖肾切除与消融后复发的影像表现及常见与少见转移部位。
核心结论
- 综述系统讨论肾细胞癌肾切除及消融治疗后随访影像方案、不同治疗方式的复发模式、影像表现及常见与少见转移部位。
- 不同机构指南在随访影像的频率、检查方式和持续时间上存在差异。
研究设计与样本
- 综述文章,检索范围与纳入文献数原文未报告。
关键影像表现/征象
- 影像引导消融方式包括射频消融、冷冻治疗和微波消融,近十年在小肿瘤治疗中日益普及。
- 综述涵盖肾细胞癌经不同方式治疗后的复发模式、影像表现以及常见与少见转移部位。
临床应用与阅片要点
- 综述讨论随访影像方案及不同治疗方式后的复发模式,供阅片时对照参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Renal cell carcinoma (RCC) is the most common renal malignancy, accounting for approximately 2% of adult malignancies and 4% of new cancer cases in the United States every year. Imaging guided ablative therapy, including radiofrequency (RF) ablation, cryotherapy and microwave has gained popularity over the last decade in treatment of small tumors. Antiangiogenic therapy has set itself to be the standard of care for many patients with metastasis these days. With hope for more research, survival rates of metastatic RCC may increase from a current 2-year survival rate of approximately 20%. Variation in imaging surveillance protocol in terms of frequency, modality, and duration is noted among guidelines developed by several organizations. In this review article, we will discuss follow-up imaging protocols, patterns of RCC recurrence following different modalities of treatment, imaging appearance, as well as usual and unusual sites of metastatic disease.
引用
- Ali O, Fishman EK, Kawamoto S, et al. Recurrent renal cell carcinoma following nephrectomy and ablation therapy: Radiology perspective. Eur J Radiol. 2018. PMID: 30292257. doi:10.1016/j.ejrad.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。